Company*
(Country;
Symbol)

Product

Description

Indication

Status (Date)


AUTOIMMUNE

Virogenomics Inc.*

VG1000

Designed to target T cells that cause inflam- mation and myelin damage in the brain and spinal cord

Multiple sclerosis

FDA granted orphan drug status to VG1000 (5/13)

CANCER

Corixa Corp. (CRXA)

Bexxar

A radioimmunotherapy; tositumomab and iodine-131 tositumomab

Non-Hodgkin's lymphoma

FDA is delaying action up to three months on the BLA (5/5)

Millennium Pharmaceuticals Inc. (MLNM)

Velcade

Bortezomib; proteasome inhibitor

Multiple myeloma

FDA granted approval (5/14)

SuperGen Inc. (SUPG)

Dacogen

Decitabine; inhibits DNA methyltransferase activity

Advanced-stage myelodysplastic syndrome

FDA designated Dacogen a fast-track product (5/12)

INFECTION

Agouron Pharmaceuticals Inc.*

Viracept (FDA-approved)

Nelfinavir mesylate; a proteas inhibitor

HIV

FDA approved a 625-mg formulation of Viracept (5/1)

MISCELLANEOUS

Genentech Inc. (NYSE:DNA)

Xolair

Omalizumab; anti-IgE therapy; a humanized monoclonal antibody

Allergic asthma

An FDA advisory panel recommended approval of Xolair (5/15)

Unigene Laboratories Inc. (OTC BB:UGNE)

Fortical

A nasal calcitonin product

Osteoporosis

FDA accepted the NDA for review (5/5)


Notes:

* Privately held

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.